E-viri
Recenzirano
Odprti dostop
-
Valgimigli, Marco; Mehran, Roxana; Franzone, Anna; da Costa, Bruno R; Baber, Usman; Piccolo, Raffaele; McFadden, Eùgene P; Vranckx, Pascal; Angiolillo, Dominick J; Leonardi, Sergio; Cao, Davide; Dangas, George D; Mehta, Shamir R; Serruys, Patrick W; Gibson, C Michael; Steg, Gabriel P; Sharma, Samin K; Hamm, Christian; Shlofmitz, Richard; Liebetrau, Christoph; Briguori, Carlo; Janssens, Luc; Huber, Kurt; Ferrario, Maurizio; Kunadian, Vijay; Cohen, David J; Zurakowski, Aleksander; Oldroyd, Keith G; Yaling, Han; Dudek, Dariuz; Sartori, Samantha; Kirkham, Brian; Escaned, Javier; Heg, Dik; Windecker, Stephan; Pocock, Stuart; Jüni, Peter
JACC. Cardiovascular interventions, 2021-Feb-22, 20210222, Letnik: 14, Številka: 4Journal Article
The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stents. The role of abbreviated DAPT followed by an oral P2Y inhibitor after PCI remains uncertain. Two randomized trials, including 14,628 patients undergoing PCI, comparing ticagrelor monotherapy with standard DAPT on centrally adjudicated endpoints were identified, and individual patient data were analyzed using 1-step fixed-effect models. The protocol was registered in PROSPERO (CRD42019143120). The primary outcomes were the composite of Bleeding Academic Research Consortium type 3 or 5 bleeding tested for superiority and, if met, the composite of all-cause death, myocardial infarction, or stroke at 1 year, tested for noninferiority against a margin of 1.25 on a hazard ratio (HR) scale. Bleeding Academic Research Consortium type 3 or 5 bleeding occurred in fewer patients with ticagrelor than DAPT (0.9% vs. 1.7%, respectively; HR: 0.56; 95% confidence interval CI: 0.41 to 0.75; p < 0.001). The composite of all-cause death, myocardial infarction, or stroke occurred in 231 patients (3.2%) with ticagrelor and in 254 patients (3.5%) with DAPT (HR: 0.92; 95% CI: 0.76 to 1.10; p < 0.001 for noninferiority). Ticagrelor was associated with lower risk for all-cause (HR: 0.71; 95% CI: 0.52 to 0.96; p = 0.027) and cardiovascular (HR: 0.68; 95% CI: 0.47 to 0.99; p = 0.044) mortality. Rates of myocardial infarction (2.01% vs. 2.05%; p = 0.88), stent thrombosis (0.29% vs. 0.38%; p = 0.32), and stroke (0.47% vs. 0.36%; p = 0.30) were similar. Ticagrelor monotherapy was associated with a lower risk for major bleeding compared with standard DAPT, without a concomitant increase in ischemic events.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.